Malaria – Pipeline Review, H1 2018

“Global Markets Direct’s, ‘Malaria – Pipeline Review, H2 2019’, provides an overview of the Malaria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malaria and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Malaria

– The report reviews pipeline therapeutics for Malaria by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Malaria therapeutics and enlists all their major and minor projects

– The report assesses Malaria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Malaria”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Malaria

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“4SC AG

AbbVie Inc

AdaptVac ApS

Akshaya Bio Inc

AlfaSigma SpA

Allergy Therapeutics Plc

Altimmune Inc

Artemis Therapeutics Inc

Artificial Cell Technologies Inc

AUM LifeTech Inc

Avalia Immunotherapies Ltd

Bharat Biotech Ltd

Brain-Gen LLC

Cadila Healthcare Ltd

Carna Biosciences Inc

Cascade Therapeutics Inc

CEL-SCI Corp

Celgene Corp

Cellics Therapeutics Inc

Cesa Alliance SA

Cilian AG

Curevac AG

Daiichi Sankyo Co Ltd

DesignMedix Inc

DMG Deutsche Malaria GmbH

Ebelle Pharmaceuticals Inc

Eisai Co Ltd

ElSohly Laboratories Inc

EpicentRx Inc

EpiVax Inc

Etna Biotech Srl

Evotec SE

Expres2ion Biotechnologies ApS

Fox Chase Chemical Diversity Center Inc

GeoVax Labs Inc

GlaxoSmithKline Plc

Hawaii Biotech Inc

Ichor Medical Systems Inc

ID Pharma Co Ltd

Immtech Pharmaceuticals Inc

Immune Modulation Inc

Imutex Ltd

IMV Inc

Innovex Therapeutics SL

IPCA Laboratories Ltd

Jacobus Pharmaceutical Co Inc

Kymab Ltd

La Jolla Pharmaceutical Company

LondonPharma Ltd

Lumen Bioscience Inc

Lyndra Inc

MediSynergics LLC

Merck KGaA

Microbiotix Inc

Mitsubishi Tanabe Pharma Corp

Mycosynthetix Inc

Mymetics Corp

Nobelpharma Co Ltd

Novartis AG

Osivax SAS

Otsuka Holdings Co Ltd

Pacific Meniuoke Biopharmaceutical Company

Pfizer Inc

Precigen Inc

Protein Potential LLC

Q BioMed Inc

Radix Pharmaceuticals Inc

Rodos BioTarget GmbH

Sanaria Inc

Sanofi

Shanghai Fosun Pharmaceutical (Group) Co Ltd

Shin Poong Pharm Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Takeda Pharmaceutical Co Ltd

Theravectys SA

Titan Pharmaceuticals Inc

Vac4All SAS

Vir Biotechnology Inc

VLP Biotech Inc

VLP Therapeutics LLC”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Malaria Overview 8

Malaria Therapeutics Development 9

Malaria Therapeutics Assessment 30

Malaria Companies Involved in Therapeutics Development 40

Malaria Drug Profiles 65

Malaria Dormant Projects 300

Malaria Discontinued Products 311

Malaria Product Development Milestones 313

Appendix 326

List of Tables

“List of Tables

Number of Products under Development for Malaria, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Malaria – Pipeline by 4SC AG, H2 2019

Malaria – Dormant Projects, H2 2019

Malaria – Discontinued Products, H2 2019

Malaria – Discontinued Products, H2 2019 (Contd..1), H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports